A novel analytical method for assessing glucose variability: using CGMS in type 1 diabetes mellitus.

McCall AL, Cox DJ, Crean J, Gloster M, Kovatchev BP

Diabetes technology & therapeutics1 Dec 2006Cited by 55 (Europe PMC)

PMID17109596DOI10.1089/dia.2006.8.644PepBankPUB-17109596

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanObservational studyEfficacy outcome
In type 1 diabetes, pramlintide lowered postprandial glucose rate of change compared with placebo.
In plain wordsIn type 1 diabetes, glucose changed more slowly after meals with pramlintide than placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreasePostprandial glucose rate of change
Study
n = 22
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
30 microg three times daily · injection · 4 weeksAs given in this study (human).
Measurements
Glucose rate of change
0.87 mg/dL/min
pramlintide
Glucose rate of change
1.21 mg/dL/min
placebo
Source sentences
Summary
The mean postprandial BG rate of change was significantly lower after 4 weeks of pramlintide treatment compared with placebo treatment (0.87 vs. 1.21 mg/dL/min, P < 0.01) without changes in average glycemia, illustrating the sensitivity of this parameter to medication effects.
1 context sentence(design, population, supporting numbers)
Summary · context
Retrospective analyses were done on 24-h CGMS profiles obtained from 22 evaluable subjects with type 1 diabetes using insulin pumps and receiving preprandial three times daily injections of placebo (n = 6) or 30 microg of pramlintide (n = 16) for 4 weeks. CGMS data were recorded at baseline, after 4…
Report a problemFND-1710959601
02HumanObservational studyEfficacy outcome
In type 1 diabetes, pramlintide treatment did not change average glycemia.
In plain wordsIn type 1 diabetes, pramlintide did not change average blood glucose.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeAverage glycemia
Study
n = 22
Outcome group
Glycemic control · Metabolic and weight
Studied dose
30 microg three times daily · injection · 4 weeksAs given in this study (human).
Source sentences
Summary
The mean postprandial BG rate of change was significantly lower after 4 weeks of pramlintide treatment compared with placebo treatment (0.87 vs. 1.21 mg/dL/min, P < 0.01) without changes in average glycemia, illustrating the sensitivity of this parameter to medication effects.
1 context sentence(design, population, supporting numbers)
Summary · context
Retrospective analyses were done on 24-h CGMS profiles obtained from 22 evaluable subjects with type 1 diabetes using insulin pumps and receiving preprandial three times daily injections of placebo (n = 6) or 30 microg of pramlintide (n = 16) for 4 weeks. CGMS data were recorded at baseline, after 4…
Report a problemFND-1710959602
03HumanObservational studyEfficacy outcome
In type 1 diabetes, the high glucose index indicated decreased hyperglycemia risk after pramlintide treatment.
In plain wordsIn type 1 diabetes, the high glucose index indicated less high blood sugar risk after pramlintide treatment.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseHyperglycemia risk index
Study
n = 22
Outcome group
Glycemic control · Metabolic and weight
Studied dose
30 microg three times daily · injection · 4 weeksAs given in this study (human).
Source sentences
Summary
The HBGI and LBGI indicated a decreased risk of hyperglycemia without a significant increase in risk of hypoglycemia after 4 weeks of pramlintide.
1 context sentence(design, population, supporting numbers)
Summary · context
Retrospective analyses were done on 24-h CGMS profiles obtained from 22 evaluable subjects with type 1 diabetes using insulin pumps and receiving preprandial three times daily injections of placebo (n = 6) or 30 microg of pramlintide (n = 16) for 4 weeks. CGMS data were recorded at baseline, after 4…
Report a problemFND-1710959603
04HumanObservational studySafety outcome
In type 1 diabetes, the low glucose index indicated no significant increase in hypoglycemia risk after pramlintide.
In plain wordsIn type 1 diabetes, the low glucose index showed no significant increase in low blood sugar risk after pramlintide.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeHypoglycemia risk index
Study
n = 22
Outcome group
Adverse events · Metabolic and weight
Studied dose
30 microg three times daily · injection · 4 weeksAs given in this study (human).
Source sentences
Summary
The HBGI and LBGI indicated a decreased risk of hyperglycemia without a significant increase in risk of hypoglycemia after 4 weeks of pramlintide.
1 context sentence(design, population, supporting numbers)
Summary · context
Retrospective analyses were done on 24-h CGMS profiles obtained from 22 evaluable subjects with type 1 diabetes using insulin pumps and receiving preprandial three times daily injections of placebo (n = 6) or 30 microg of pramlintide (n = 16) for 4 weeks. CGMS data were recorded at baseline, after 4…
Report a problemFND-1710959604

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.